• PRAKASH K. SONI

Presently available conventional ocular dosage forms, viz., solution, suspension, and ointment, etc. possess drawbacks of precorneal drug elimination, variability in efficacy, and blurred vision on application and thereby frequently administered to achieve desired ocular drug bioavailability. The in-situ gel forming solution (GFS) undergoes a sol-gel transition in cul-de-sac of eye and therefore, overcomes the above drawbacks. In present investigation, an ion-activated in-situ gelling topical ocular formulation of gatifloxacin sesquihydrate was developed with an object to provide a long pre-corneal retention time and sustained release drug delivery. Gellan gum as ion-activated in-situ gelling agent and HPMC K100M as mucoadhesive release retardant were used in the formulation development. The developed formulations were evaluated for clarity, pH, drug content, isotonicity, in-vitro gelation, in-vitro drug release and ocular irritancy. The developed products exhibited an instant viscoelastic gelation in contact with simulated lachrymal fluid (SLF) with sustained drug release profile over 8 h period and passed the HET-CAM ocular irritancy test.

Gatifloxacin sesquihydrate, In-situ gel, Gellan gum, Simulated lachrymal fluid, HET-CAM.

"ION-ACTIVATED IN-SITU GEL FORMULATION OF GATIFLOXACIN FOR SUSTAINED RELEASE OCULAR DRUG DELIVERY", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 4, page no.1906-1914, April-2019, Available :http://www.jetir.org/papers/JETIR1904S78.pdf

"ION-ACTIVATED IN-SITU GEL FORMULATION OF GATIFLOXACIN FOR SUSTAINED RELEASE OCULAR DRUG DELIVERY", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 4, page no. pp1906-1914, April-2019, Available at : http://www.jetir.org/papers/JETIR1904S78.pdf